Aggressive neuroblastomas have high p110alpha but low p110delta and p55alpha/p50alpha protein levels compared to low stage neuroblastomas

Table 1 Clinical data

Patient	INSS	INRG	Age at diagnosis (months)	Follow up or outcome change (months)	Outcome	1p loss	MNA	11q loss	Origin
26R9	1	L	2	91	NED	neg	neg	neg	Adrenal gland
25R9	2	L	111	95	NED	neg	neg	neg	NA
20R9	2	L	3	113	NED	neg	neg	NA	NA
27R7	2	L	0	92	NED	neg	neg	neg	Intraspinal abdominal
33R7	2	L	3	92	NED	neg	neg	neg	NA
13E8	2	L	32	202	NED	neg	neg	neg	NA
15E7	3	L	0	0	DSC	neg	neg	neg	NA
15E3	3	L	12	195	NED	neg	neg	neg	NA
25R0	3	L	1	97	NED	neg	neg	neg	Thorax
13E6	3	L	48	12	DOD	pos	pos	pos	NA
11R4	3	L	15	27	DOD	pos	pos	neg	NA
10R8	3	L	80	59	DOD	neg	neg	pos	NA
9R9	3	L	24	21	DOD	pos	neg	pos	NA
10R2	4	M	15	12	DOD	pos	pos	neg	NA
15R3	4	M	28	9	DOD	pos	neg	pos	Adrenal gland
34R0	4	M	64	11	DOD	neg	neg	neg	Abdominal
17R2	4	M	80	45	DOD	neg	neg	pos	NA
26R8	4	M	21	18	DOD	pos	pos	NA	NA
28R8	4	M	29	26	DOD	neg	neg	pos	Adrenal gland
16E9	4	M	19	5	DOD	neg	pos	neg	NA
39R1	4	M	22	29	NED	pos	pos	neg	Abdominal

Abbreviations: INSS, International neuroblastoma staging system; INRG, International neuroblastoma risk group; MNA, MYCN amplification; NA, Information not available; L, Localized; M, Metastasized; NED, No evidence of disease; DOD, Dead of disease; DSC, Dead by surgical complications; pos, Positive; neg, Negative.